Tuesday, 23 July 2019

Ceisteanna (1408)

Marc MacSharry


1408. Deputy Marc MacSharry asked the Minister for Health further to Parliamentary Question No. 299 of 10 July 2019, if the HSE has considered a revised representation for the drug Tagrisso as a second line therapy for non-small cell lung cancer at recent drug group or senior leadership meetings; the dates such meetings took place or are scheduled to take place; the recommendation and decision made with regard to the reimbursement of the drug if a meeting took place; and if he will make a statement on the matter. [32804/19]

Amharc ar fhreagra

Freagraí scríofa (Ceist ar Health)

The HSE has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drug schemes, in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013; therefore, the matter has been referred to the HSE for reply to the Deputy.